Table 4.

Patient characteristics of a subgroup of 28 patients according to EGFR mutation status, number of CA repeats in intron 1, EGFR and caveolin-1 mRNA levels, and EGFR gene copy numbers

Wild-type EGFR, n (%)Mutated EGFR, n (%)P
No. patients199
Age (y)
    <6510 (52)6 (66.6)NS
    ≥659 (48)3 (33.3)
Sex
    Male15 (79)4 (45)NS
    Female4 (21)5 (55)
Ethnicity
    Caucasian8 (42)4 (45)NS
    Asian11 (58)5 (55)
Histology
    Adenocarcinoma16 (85)9 (100)NS
    Large cell carcinoma1 (5)0
    Squamous cell carcinoma2 (10)0
Smoking status
    Smoker15 (79)3 (33.3)0.035
    Nonsmoker4 (21)6 (66.6)
Response to gefitinib
    Yes2 (11)8 (88)<0.0001
    No16 (84)1 (12)
    Nonevaluable1 (5)
Duration of gefitinib response (wk)
    Median (range)6.93 (0.2-27.6)7.73 (1.05-15.63)NS
CA repeats in intron 1
    <193 (20.5)*0 (-)*NS
    ≥1911 (79.5)*7 (100)*
EGFR mRNA levels
    No. patients1580.087
    Median (range)2.61 (0.42-23.09)*5.04 (1.79-47.37)*
Caveolin-1 mRNA levels
    No. patients148NS
    Median (range)0.71 (0.06-2.16)*0.55 (0.19-1.07)*
EGFR gene copy numbers
    Increased4 (21)5 (55)0.087
    Normal15 (79)4 (45)
  • Abbreviation: NS, not significant.

  • * Disparity between some figures is due to the lower availability of tumor tissue in some patients.